Methimazole and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Methimazole (methimazole), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Dexamethasone, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Methimazole. It is created by eHealthMe based on reports of 7,420 people who have side effects when taking Methimazole from the FDA, and is updated regularly.

What is Methimazole?

Methimazole has active ingredients of methimazole. It is often used in hyperthyroidism. eHealthMe is studying from 8,016 Methimazole users. Check the latest studies of Methimazole.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,509 drugs and 1,636 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

7,420 people reported to have side effects when taking Methimazole.
Among them, 23 people (0.31%) have Malignant neoplasm progression.

Could Methimazole cause Malignant neoplasm progression?

Among these 23 people:

How long have people been on Methimazole when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Methimazole? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Malignant neoplasm progression when taking Methimazole? *

What are other drugs people take besides Methimazole? *

What are other side effects people have besides Malignant neoplasm progression? *

Joint Pain: 4 people, 17.39%
High Blood Pressure: 4 people, 17.39%
Fatigue (feeling of tiredness): 4 people, 17.39%
Constipation: 4 people, 17.39%
Tumor Lysis Syndrome: 3 people, 13.04%
Headache (pain in head): 3 people, 13.04%
Thrombocytopenia (decrease of platelets in blood): 3 people, 13.04%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 13.04%
Drug Hypersensitivity: 3 people, 13.04%
Intestinal Obstruction: 3 people, 13.04%

What are the existing conditions these people have? *

Prostate Cancer: 4 people, 17.39%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 17.39%
Pain: 3 people, 13.04%
Metabolic Disorder (an abnormal function and pattern of body fat. insulin resistance refers to the diminished ability of cells to respond to the action of insulin in promoting the transport of the sugar glucose, from blood into muscles and other tissues): 2 people, 8.70%
Renal Cell Carcinoma (a kidney cancer): 2 people, 8.70%
Ovarian Cancer (cancer of ovary): 2 people, 8.70%
Heart Disease: 2 people, 8.70%
Cerebrovascular Disorder (disease of brain): 2 people, 8.70%
Constipation: 2 people, 8.70%
Malignant Melanoma (skin cancer rises from melancytes): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Methimazole and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Methimazole:

Methimazole (8,016 reports)

Browse all side effects of Methimazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,509 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,636 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methimazole (the active ingredients of Methimazole) and Methimazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.